Slide 1: Immuron CEO Steven Lydeamore to present at AusBioInvest
Level 3, 62 Lygon Street, Carlton South, Victoria AUSTRALIA 3053 www.immuron.com ABN: 80 063 114 045 Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735 Immuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia, October 27 , 2022 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN
Slide 2: About Immuron and Travelan
Page 2 of 2 About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. About Travelan® Travelan ® is a
Slide 3: Investor Presentation, 27 October 2022
1 1 INVESTOR PRESENTATION 27 OCTOBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC ersonal use only
Slide 4: Forward-looking statements
2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections . Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended t
Slide 5: Executive Summary
3 EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview • Two commercially available oral immunotherapeutic products – Tr
Slide 6: Travelan & Florastor CampETEC
4 Travelan® & Florastor® CampETEC • The business is completing an assessment of the entire product portfolio, target markets, competitive advantage and, key growth drivers • US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the militar
Slide 7: Lumanity Opportunity Assessment for IMM-124E
5 Lumanity* Opportunity Assessment for IMM - 124E • Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need • Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% prot
Slide 8: Addressable Market & Industry Overview
6 ADDRESSABLE MARKET & INDUSTRY OVERVIEW Billion Dollar Market Travelers diarrhea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns * IQVIA Consumer Health Category QuickView MAT Q1 2019 ** IMC Company Report - Travela
Slide 9: =) O > wv Zz <x —L — Aju asn jeuosie
=) O > wv Zz <x —L — Aju asn jeuosie
Slide 10: Scientific References
8 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan as a broad Spectrum anti -